A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors
Clinical trial NCT05763004 · COMPLETED
Trial details
- NCT number
- NCT05763004
- Sponsor
- ImmunOs Therapeutics AG
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-15
- Primary completion
- 2026-05-30
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.